The Relevance of Metals in the Pathophysiology of Neurodegeneration, Pathological Considerations

International Review of Neurobiology

Volumn 110, Issue , 2013, Pages 1-47

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Chelation therapy; Metal ions; Neurodegeneration; Oxidative stress; Protein aggregation

Indexed keywords

ALPHA SYNUCLEIN; ALUMINUM; AMYLOID BETA PROTEIN; CHELATING AGENT; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; FRATAXIN; IRON; MANGANESE; REACTIVE OXYGEN METABOLITE; ZINC;

ALUMINUM METABOLISM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COPPER METABOLISM; HUMAN; HUNTINGTON CHOREA; IRON BINDING CAPACITY; IRON STORAGE; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SOD1 GENE; ZINC METABOLISM;

CHELATION THERAPY; METAL IONS; NEURODEGENERATION; OXIDATIVE STRESS; PROTEIN AGGREGATION;

ANIMALS; CHELATING AGENTS; CHELATION THERAPY; HUMANS; METALS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 84887241977     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410502-7.00002-8     Document Type: Chapter

References (340)

1. Acevedo K.M., Hung Y.H., Dalziel A.H., Li Q.X., Laughton K., Wikhe K., et al. Copper promotes the trafficking of the amyloid precursor protein. Journal of Biological Chemistry 2011, 286(10):8252-8262.
2. Ahmad A., Burns C.S., Fink A.L., Uversky V.N. Peculiarities of copper binding to alpha-synuclein. Journal of Biomolecular Structure and Dynamics 2012, 29(4):825-842.
3. Allsop D., Mayes J., Moore S., Masad A., Tabner B.J. Metal-dependent generation of reactive oxygen species from amyloid proteins implicated in neurodegenerative disease. Biochemical Society Transactions 2008, 36(Pt 6):1293-1298.
4. Al-Radaideh A.M., Wharton S.J., Lim S.Y., Tench C.R., Morgan P.S., Bowtell R.W., et al. Increased iron accumulation occurs in the earliest stages of demyelinating disease: An ultra-high field susceptibility mapping study in Clinically Isolated Syndrome. Multiple Sclerosis 2012, 19:896-903.
5. Ansari M.A., Scheff S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. Journal of Neuropathology and Experimental Neurology 2010, 69(2):155-167.
6. Aremu D.A., Meshitsuka S. Some aspects of astroglial functions and aluminum implications for neurodegeneration. Brain Research Reviews 2006, 52(1):193-200.
7. Arreguin S., Nelson P., Padway S., Shirazi M., Pierpont C. Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease. Journal of Inorganic Biochemistry 2009, 103(1):87-93.
8. Aschner M., Erikson K.M., Herrero Hernandez E., Tjalkens R. Manganese and its role in Parkinson's disease: From transport to neuropathology. Neuromolecular Medicine 2009, 11(4):252-266.
9. Atwood C.S., Robinson S.R., Smith M.A. Amyloid-beta: Redox-metal chelator and antioxidant. Journal of Alzheimer's Disease 2002, 4(3):203-214.
10. Ayton S., Lei P., Bush A.I. Metallostasis in Alzheimer's disease. Free Radical Biology & Medicine 2013, 62:76-89.
11. Badrick A.C., Jones C.E. Reorganizing metals: The use of chelating compounds as potential therapies for metal-related neurodegenerative disease. Current Topics in Medicinal Chemistry 2011, 11(5):543-552.
12. Bagnato F., Hametner S., Welch E.B. Visualizing iron in multiple sclerosis. Magnetic Resonance Imaging 2013, 31(3):376-384.
13. Bakshi R., Thompson A.J., Rocca M.A., Pelletier D., Dousset V., Barkhof F., et al. MRI in multiple sclerosis: Current status and future prospects. Lancet Neurology 2008, 7(7):615-625.
14. Barnham K.J., Bush A.I. Metals in Alzheimer's and Parkinson's diseases. Current Opinion in Chemical Biology 2008, 12(2):222-228.
15. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nature Reviews Drug Discovery 2004, 3(3):205-214.
16. Barsukova A.G., Bourdette D., Forte M. Mitochondrial calcium and its regulation in neurodegeneration induced by oxidative stress. European Journal of Neuroscience 2011, 34(3):437-447.
17. Bartzokis G., Tishler T.A., Shin I.S., Lu P.H., Cummings J.L. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Annals of the New York Academy of Sciences 2004, 1012:224-236.
18. Batista-Nascimento L., Pimentel C., Menezes R.A., Rodrigues-Pousada C. Iron and neurodegeneration: From cellular homeostasis to disease. Oxidative Medicine and Cellular Longevity 2012, 2012:128647.
19. Bauer P.O., Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. Journal of Neurochemistry 2009, 110(6):1737-1765.
20. Beach T.G., Walker D.G., Sue L.I., Newell A., Adler C.C., Joyce J.N. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. Journal of Neuropathology and Experimental Neurology 2004, 63(4):329-337.
21. Belkacemi A., Ramassamy C. Time sequence of oxidative stress in the brain from transgenic mouse models of Alzheimer's disease related to the amyloid-beta cascade. Free Radical Biology & Medicine 2012, 52(3):593-600.
22. Bender A., Desplats P., Spencer B., Rockenstein E., Adame A., Elstner M., et al. TOM40 mediates mitochondrial dysfunction induced by alpha-synuclein accumulation in Parkinson's disease. PLoS One 2013, 8(4):e62277.
23. Berg D., Riederer P., Gerlach M. Contribution of disturbed iron metabolism to the pathogenesis of Parkinson's disease. Future Neurology 2008, 3:447-461.
24. Beyer N., Coulson D.T., Heggarty S., Ravid R., Hellemans J., Irvine G.B., et al. Zinc transporter mRNA levels in Alzheimer's disease postmortem brain. Journal of Alzheimer's Disease 2012, 29(4):863-873.
25. Bharathi P., Vasudevaraju P., Govindaraju M., Palanisamy A.P., Sambamurti K., Rao K.S. Molecular toxicity of aluminium in relation to neurodegeneration. The Indian Journal of Medical Research 2008, 128(4):545-556.
26. Binolfi A., Rodriguez E.E., Valensin D., D'Amelio N., Ippoliti E., Obal G., et al. Bioinorganic chemistry of Parkinson's disease: Structural determinants for the copper-mediated amyloid formation of alpha-synuclein. Inorganic Chemistry 2010, 49(22):10668-10679.
27. Bisaglia M., Tessari I., Mammi S., Bubacco L. Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. Neuromolecular Medicine 2009, 11(4):239-251.
28. Bitanihirwe B.K., Cunningham M.G. Zinc: The brain's dark horse. Synapse 2009, 63(11):1029-1049.
29. Bjorklund N.L., Sadagoparamanujam V.M., Taglialatela G. Selective, quantitative measurement of releasable synaptic zinc in human autopsy hippocampal brain tissue from Alzheimer's disease patients. Journal of Neuroscience Methods 2012, 203(1):146-151.
30. Boelmans K., Holst B., Hackius M., Finsterbusch J., Gerloff C., Fiehler J., et al. Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy. Movement Disorders 2012, 27(3):421-427.
31. Bolognin S., Messori L., Drago D., Gabbiani C., Cendron L., Zatta P. Aluminum, copper, iron and zinc differentially alter amyloid-Abeta(1-42) aggregation and toxicity. The International Journal of Biochemistry & Cell Biology 2011, 43(6):877-885.
32. Bolognin S., Messori L., Zatta P. Metal ion physiopathology in neurodegenerative disorders. Neuromolecular Medicine 2009, 11(4):223-238.
33. Bonda D.J., Lee H.G., Blair J.A., Zhu X., Perry G., Smith M.A. Role of metal dyshomeostasis in Alzheimer's disease. Metallomics 2011, 3(3):267-270.
34. Bowman A.B., Kwakye G.F., Hernandez E.H., Aschner M. Role of manganese in neurodegenerative diseases. Journal of Trace Elements in Medicine and Biology 2011, 25(4):191-203.
35. Breydo L., Uversky V.N. Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases. Metallomics 2011, 3(11):1163-1180.
36. Brown D.R. Brain proteins that mind metals: A neurodegenerative perspective. Dalton Transactions 2009, 7(21):4069-4076.
37. Burton N.C., Guilarte T.R. Manganese neurotoxicity: Lessons learned from longitudinal studies in nonhuman primates. Environmental Health Perspectives 2009, 117(3):325-332.
38. Bush A.I. The metallobiology of Alzheimer's disease. Trends in Neurosciences 2003, 26(4):207-214.
39. Bush A.I. The metal theory of Alzheimer's disease. Journal of Alzheimer's Disease 2013, 33(Suppl 1):S277-S281.
40. Bush A.I., Curtain C.C. Twenty years of metallo-neurobiology: Where to now?. European Biophysics Journal 2008, 37(3):241-245.
41. Calabresi P., Ammassari-Teule M., Gubellini P., Sancesario G., Morello M., Centonze D., et al. A synaptic mechanism underlying the behavioral abnormalities induced by manganese intoxication. Neurobiology of Disease 2001, 8(3):419-432.
42. Cali T., Ottolini D., Brini M. Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease. Biofactors 2011, 37(3):228-240.
43. Campbell A. The potential role of aluminium in Alzheimer's disease. Nephrology, Dialysis, Transplantation 2002, 17(Suppl 2):17-20.
44. Campbell A. The role of aluminum and copper on neuroinflammation and Alzheimer's disease. Journal of Alzheimer's Disease 2006, 10(2-3):165-172.
45. Capasso M., Jeng J.M., Malavolta M., Mocchegiani E., Sensi S.L. Zinc dyshomeostasis: A key modulator of neuronal injury. Journal of Alzheimer's Disease 2005, 8(2):93-108. discussion 209-115.
46. Caragounis A., Price K.A., Soon C.P., Filiz G., Masters C.L., Li Q.X., et al. Zinc induces depletion and aggregation of endogenous TDP-43. Free Radical Biology & Medicine 2010, 48(9):1152-1161.
47. Carri M.T., Ferri A., Cozzolino M., Calabrese L., Rotilio G. Neurodegeneration in amyotrophic lateral sclerosis: The role of oxidative stress and altered homeostasis of metals. Brain Research Bulletin 2003, 61(4):365-374.
48. Castellani R.J., Lee H.G., Perry G., Smith M.A. Antioxidant protection and neurodegenerative disease: The role of amyloid-beta and tau. American Journal of Alzheimer's Disease and Other Dementias 2006, 21(2):126-130.
49. Castellani R.J., Moreira P.I., Liu G., Dobson J., Perry G., Smith M.A., et al. Iron: The Redox-active center of oxidative stress in Alzheimer disease. Neurochemical Research 2007, 32(10):1640-1645.
50. Castellani R.J., Siedlak S.L., Perry G., Smith M.A. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathologica 2000, 100(2):111-114.
51. Cerpa W., Varela-Nallar L., Reyes A.E., Minniti A.N., Inestrosa N.C. Is there a role for copper in neurodegenerative diseases?. Molecular Aspects of Medicine 2005, 26(4-5):405-420.
52. Chakraborty S., Aschner M. Altered manganese homeostasis: Implications for BLI-3-dependent dopaminergic neurodegeneration and SKN-1 protection in C. elegans. Journal of Trace Elements in Medicine and Biology 2012, 26(2-3):183-187.
53. Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M., Sudhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123(3):383-396.
54. Chang D.T., Rintoul G.L., Pandipati S., Reynolds I.J. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiology of Disease 2006, 22(2):388-400.
55. Chassaing S., Collin F., Dorlet P., Gout J., Hureau C., Faller P. Copper and heme-mediated a-beta toxicity: Redox chemistry, a-beta oxidations and anti-ROS compounds. Current Topics in Medicinal Chemistry 2012, 12(22):2573-2595.
56. Chattopadhyay M., Valentine J.S. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxidants & Redox Signaling 2009, 11(7):1603-1614.
57. Craddock T.J., Tuszynski J.A., Chopra D., Casey N., Goldstein L.E., Hameroff S.R., et al. The zinc dyshomeostasis hypothesis of Alzheimer's disease. PLoS One 2012, 7(3):e33552.
58. Craelius W., Migdal M.W., Luessenhop C.P., Sugar A., Mihalakis I. Iron deposits surrounding multiple sclerosis plaques. Archives of Pathology & Laboratory Medicine 1982, 106(8):397-399.
59. Crichton R.R., Dexter D.T., Ward R.J. Brain iron metabolism and its perturbation in neurological diseases. Journal of Neural Transmission 2011, 118(3):301-314.
60. Cuajungco M.P., Faget K.Y. Zinc takes the center stage: Its paradoxical role in Alzheimer's disease. Brain Research. Brain Research Reviews 2003, 41(1):44-56.
61. Cuajungco M.P., Goldstein L.E., Nunomura A., Smith M.A., Lim J.T., Atwood C.S., et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. Journal of Biological Chemistry 2000, 275(26):19439-19442.
62. Cuajungco M.P., Lees G.J. Nitric oxide generators produce accumulation of chelatable zinc in hippocampal neuronal perikarya. Brain Research 1998, 799(1):118-129.
63. Davies K.M., Hare D.J., Cottam V., Chen N., Hilgers L., Halliday G., et al. Localization of copper and copper transporters in the human brain. Metallomics 2013, 5(1):43-51.
64. De Sole P., Rossi C., Chiarpotto M., Ciasca G., Bocca B., Alimonti A., et al. Possible relationship between Al/ferritin complex and Alzheimer's disease. Clinical Biochemistry 2013, 46(1-2):89-93.
65. Dexter D.T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., et al. Decreased ferritin levels in brain in Parkinson's disease. Journal of Neurochemistry 1990, 55(1):16-20.
66. Dexter D.T., Sian J., Jenner P., Marsden C.D. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Advances in Neurology 1993, 60:273-281.
67. Dexter D. Parkinson's disease: Involvement of iron and oxidative stress. Mechanisms and metal involvement in neurodegenerative diseases 2013, 58-79. The Royal Society of Chemistry, London, UK. R. Ward, R. Crichton, D. Dexter (Eds.).
68. Dickens M.G., Franz K.J. A prochelator activated by hydrogen peroxide prevents metal-induced amyloid Beta aggregation. Chembiochem 2010, 11(1):59-62.
69. Dobson A.W., Erikson K.M., Aschner M. Manganese neurotoxicity. Annals of the New York Academy of Sciences 2004, 1012:115-128.
70. Domingo J.L. Aluminum and other metals in Alzheimer's disease: A review of potential therapy with chelating agents. Journal of Alzheimer's Disease 2006, 10(2-3):331-341.
71. Double K.L., Reyes S., Werry E.L., Halliday G.M. Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?. Progress in Neurobiology 2010, 92(3):316-329.
72. Drago D., Bolognin S., Zatta P. Role of metal ions in the abeta oligomerization in Alzheimer's disease and in other neurological disorders. Current Alzheimer Research 2008, 5(6):500-507.
73. Duce J.A., Tsatsanis A., Cater M.A., James S.A., Robb E., Wikhe K., et al. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010, 142(6):857-867.
74. Duda J.E., Jellinger K.A. Neurodegeneration with brain iron accumulation. Neurodegeneration: The molecular pathology of dementia and movement disorders 2011, 446-455. Blackwell, Oxford. 2nd ed. D.W. Dickson, R.O. Weller (Eds.).
75. Dusek P., Jankovic J., Le W. Iron dysregulation in movement disorders. Neurobiology of Disease 2012, 46(1):1-18.
76. Dusek P., Schneider S.A. Neurodegeneration with brain iron accumulation. Current Opinion in Neurology 2012, 25(4):499-506.
77. Eibl J.K., Abdallah Z., Ross G.M. Zinc-metallothionein: A potential mediator of antioxidant defence mechanisms in response to dopamine-induced stress. Canadian Journal of Physiology and Pharmacology 2010, 88(3):305-312.
78. Erikson K.M., Syversen T., Aschner J.L., Aschner M. Interactions between excessive manganese exposures and dietary iron-deficiency in neurodegeneration. Environmental Toxicology and Pharmacology 2005, 19(3):415-421.
79. Eskici G., Axelsen P.H. Copper and oxidative stress in the pathogenesis of Alzheimer's disease. Biochemistry 2012, 51(32):6289-6311.
80. Evans R.W., Kong X., Hider R.C. Iron mobilization from transferrin by therapeutic iron chelating agents. Biochimica et Biophysica Acta 2012, 1820(3):282-290.
81. Exley C. The aluminium-amyloid cascade hypothesis and Alzheimer's disease. Subcellular Biochemistry 2005, 38:225-234.
82. Exley C. Aluminium and iron, but neither copper nor zinc, are key to the precipitation of beta-sheets of Abeta_{42} in senile plaque cores in Alzheimer's disease. Journal of Alzheimer's Disease 2006, 10(2-3):173-177.
83. Faller P. Copper and zinc binding to amyloid-beta: Coordination, dynamics, aggregation, reactivity and metal-ion transfer. Chembiochem 2009, 10(18):2837-2845.
84. Farina M., Avila D.S., da Rocha J.B., Aschner M. Metals, oxidative stress and neurodegeneration: A focus on iron, manganese and mercury. Neurochemistry International 2013, 62(5):575-594.
85. Fasano M., Bergamasco B., Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. Journal of Neurochemistry 2006, 96(4):909-916.
86. Faucheux B.A., Martin M.E., Beaumont C., Hauw J.J., Agid Y., Hirsch E.C. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. Journal of Neurochemistry 2003, 86(5):1142-1148.
87. Faucheux B.A., Martin M.E., Beaumont C., Hunot S., Hauw J.J., Agid Y., et al. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. Journal of Neurochemistry 2002, 83(2):320-330.
88. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
89. Febbraro F., Giorgi M., Caldarola S., Loreni F., Romero-Ramos M. alpha-Synuclein expression is modulated at the translational level by iron. Neuroreport 2012, 23(9):576-580.
90. Federico A., Cardaioli E., Da Pozzo P., Formichi P., Gallus G.N., Radi E. Mitochondria, oxidative stress and neurodegeneration. Journal of Neurological Sciences 2012, 322(1-2):254-262.
91. Filosto M., Scarpelli M., Cotelli M.S., Vielmi V., Todeschini A., Gregorelli V., et al. The role of mitochondria in neurodegenerative diseases. Journal of Neurology 2011, 258(10):1763-1774.
92. Firdaus W.J., Wyttenbach A., Giuliano P., Kretz-Remy C., Currie R.W., Arrigo A.P. Huntingtin inclusion bodies are iron-dependent centers of oxidative events. The FEBS Journal 2006, 273(23):5428-5441.
93. Fischer M.T., Sharma R., Lim J.L., Haider L., Frischer J.M., Drexhage J., et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012, 135(Pt 3):886-899.
94. Fitsanakis V.A., Au C., Erikson K.M., Aschner M. The effects of manganese on glutamate, dopamine and gamma-aminobutyric acid regulation. Neurochemistry International 2006, 48(6-7):426-433.
95. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Natale G., et al. Recent knowledge on molecular components of Lewy bodies discloses future therapeutic strategies in Parkinson's disease. Current Drug Targets. CNS and Neurological Disorders 2003, 2(3):149-152.
96. Frazzini V., Rockabrand E., Mocchegiani E., Sensi S.L. Oxidative stress and brain aging: Is zinc the link?. Biogerontology 2006, 7(5-6):307-314.
97. Friedman A., Galazka-Friedman J., Koziorowski D. Iron as a cause of Parkinson disease-A myth or a well established hypothesis?. Parkinsonism & Related Disorders 2009, 15(Suppl 3):S212-S214.
98. Gaeta A., Hider R.C. The crucial role of metal ions in neurodegeneration: The basis for a promising therapeutic strategy. British Journal of Pharmacology 2005, 146(8):1041-1059.
99. Gaier E.D., Eipper B.A., Mains R.E. Copper signaling in the mammalian nervous system: Synaptic effects. Journal of Neuroscience Research 2013, 91(1):2-19.
100. Gakh O., Park S., Liu G., Macomber L., Imlay J.A., Ferreira G.C., et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Human Molecular Genetics 2006, 15(3):467-479.
101. Galazka-Friedman J., Bauminger E.R., Szlachta K., Friedman A. The role of iron in neurodegeneration-Mossbauer spectroscopy, electron microscopy, enzyme-linked immunosorbent assay and neuroimaging studies. Journal of Physics: Condensed Matter 2012, 24(24):244106.
102. Gavrin L.K., Denny R.A., Saiah E. Small molecules that target protein misfolding. Journal of Medicinal Chemistry 2012, 55(24):10823-10843.
103. Geldenhuys W.J., Van der Schyf C.J. Designing drugs with multi-target activity: The next step in the treatment of neurodegenerative disorders. Expert Opinion on Drug Discovery 2013, 8(2):115-129.
104. Geldenhuys W.J., Van der Schyf C.J. Rationally designed multi-targeted agents against neurodegenerative diseases. Current Medicinal Chemistry 2013, 20(13):1662-1672.
105. Gemmati D., Zeri G., Orioli E., De Gaetano F.E., Salvi F., Bartolomei I., et al. Polymorphisms in the genes coding for iron binding and transporting proteins are associated with disability, severity, and early progression in multiple sclerosis. BMC Medical Genetics 2012, 13:70.
106. Geng J., Li M., Wu L., Ren J., Qu X. Liberation of copper from amyloid plaques: Making a risk factor useful for Alzheimer's disease treatment. Journal of Medicinal Chemistry 2012, 55(21):9146-9155.
107. Gille G., Reichmann H. Iron-dependent functions of mitochondria-Relation to neurodegeneration. Journal of Neural Transmission 2011, 118(3):349-359.
108. Giordana M.T., Piccinini M., Grifoni S., De Marco G., Vercellino M., Magistrello M., et al. TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathology 2010, 20(2):351-360.
109. Gleichmann M., Mattson M.P. Neuronal calcium homeostasis and dysregulation. Antioxidants & Redox Signaling 2011, 14(7):1261-1273.
110. Golts N., Snyder H., Frasier M., Theisler C., Choi P., Wolozin B. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. Journal of Biological Chemistry 2002, 277(18):16116-16123.
111. Gomes C.M. Protein misfolding in disease and small molecule therapies. Current Topics in Medicinal Chemistry 2013, 12(22):2460-2469.
112. Gonsette R.E. Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity. Journal of Neurological Sciences 2008, 274(1-2):48-53.
113. Gotz M.E., Double K., Gerlach M., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Annals of the New York Academy of Sciences 2004, 1012:193-208.
114. Gower-Winter S.D., Levenson C.W. Zinc in the central nervous system: From molecules to behavior. Biofactors 2012, 38(3):186-193.
115. Greenough M.A., Camakaris J., Bush A.I. Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochemistry International 2012, 62:540-555.
116. Gregory A., Hayflick S.J. Genetics of neurodegeneration with brain iron accumulation. Current Neurology and Neuroscience Reports 2011, 11(3):254-261.
117. Guilarte T.R. Manganese and Parkinson's disease: A critical review and new findings. Environmental Health Perspectives 2010, 118(8):1071-1080.
118. Gupta V.B., Anitha S., Hegde M.L., Zecca L., Garruto R.M., Ravid R., et al. Aluminium in Alzheimer's disease: Are we still at a crossroad?. Cellular and Molecular Life Sciences 2005, 62(2):143-158.
119. Haacke E.M., Makki M., Ge Y., Maheshwari M., Sehgal V., Hu J., et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. Journal of Magnetic Resonance Imaging 2009, 29(3):537-544.
120. Habib C.A., Liu M., Bawany N., Garbern J., Krumbein I., Mentzel H.J., et al. Assessing abnormal iron content in the deep gray matter of patients with multiple sclerosis versus healthy controls. AJNR. American Journal of Neuroradiology 2012, 33(2):252-258.
121. Hagemeier J., Geurts J.J., Zivadinov R. Brain iron accumulation in aging and neurodegenerative disorders. Expert Review of Neurotherapeutics 2012, 12(12):1467-1480.
122. Haider L., Fischer M.T., Frischer J.M., Bauer J., Hoftberger R., Botond G., et al. Oxidative damage in multiple sclerosis lesions. Brain 2011, 134(Pt 7):1914-1924.
123. Hajji N., Calvert C., Ritchie C.W., Sastre M. The role of metals in Alzheimer's disease. Mechanisms and metal involvement in neurodegenerative diseases 2013, 80-97. The Royal Society of Chemistry, London, UK. R. Ward, R. Crichton, D. Dexter (Eds.).
124. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. Journal of Neurochemistry 1958, 3(1):41-51.
125. Halliday G.M., Ophof A., Broe M., Jensen P.H., Kettle E., Fedorow H., et al. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005, 128(Pt 11):2654-2664.
126. Halliwell B. Oxidative stress and neurodegeneration: Where are we now?. Journal of Neurochemistry 2006, 97(6):1634-1658.
127. HaMai D., Bondy S.C. Oxidative basis of manganese neurotoxicity. Annals of the New York Academy of Sciences 2004, 1012:129-141.
128. Hametner S., Wimmer I., Haider L., Pfeifenbring S., Bruck W., Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain 2013, Annals of Neurology.
129. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
130. Hare D., Ayton S., Bush A., Lei P. A delicate balance: Iron metabolism and diseases of the brain. Frontiers in Aging Neuroscience 2013, 5:34.
131. Hashimoto M., Takeda A., Hsu L.J., Takenouchi T., Masliah E. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. Journal of Biological Chemistry 1999, 274(41):28849-28852.
132. Hauptmann S., Scherping I., Drose S., Brandt U., Schulz K.L., Jendrach M., et al. Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiology of Aging 2009, 30(10):1574-1586.
133. Heli H., Mirtorabi S., Karimian K. Advances in iron chelation: An update. Expert Opinion on Therapeutic Patents 2011, 21(6):819-856.
134. Henshall T.L., Tucker B., Lumsden A.L., Nornes S., Lardelli M.T., Richards R.I. Selective neuronal requirement for huntingtin in the developing zebrafish. Human Molecular Genetics 2009, 18(24):4830-4842.
135. Hirose W., Ikematsu K., Tsuda R. Age-associated increases in heme oxygenase-1 and ferritin immunoreactivity in the autopsied brain. Legal Medicine (Tokyo, Japan) 2003, 5(Suppl.1):S360-S366.
136. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection?. Lancet Neurology 2009, 8(4):382-397.
137. Hirsch E.C., Jenner P., Przedborski S. Pathogenesis of Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society 2013, 28(1):24-30.
138. Hogarth P., Gregory A., Kruer M.C., Sanford L., Wagoner W., Natowicz M.R., et al. New NBIA subtype: Genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 2013, 80(3):268-275.
139. Honda K., Casadesus G., Petersen R.B., Perry G., Smith M.A. Oxidative stress and redox-active iron in Alzheimer's disease. Annals of the New York Academy of Sciences 2004, 1012:179-182.
140. Horowitz M.P., Greenamyre J.T. Mitochondrial iron metabolism and its role in neurodegeneration. Journal of Alzheimer's Disease 2010, 20(Suppl 2):S551-S568.
141. House E., Collingwood J., Khan A., Korchazkina O., Berthon G., Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. Journal of Alzheimer's Disease 2004, 6(3):291-301.
142. House E., Esiri M., Forster G., Ince P.G., Exley C. Aluminium, iron and copper in human brain tissues donated to the Medical Research Council's Cognitive Function and Ageing Study. Metallomics 2012, 4(1):56-65.
143. Huang M.L., Becker E.M., Whitnall M., Suryo Rahmanto Y., Ponka P., Richardson D.R. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(38):16381-16386.
144. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., et al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. Journal of Biological Chemistry 1999, 274(52):37111-37116.
145. Huang C.C., Weng Y.H., Lu C.S., Chu N.S., Yen T.C. Dopamine transporter binding in chronic manganese intoxication. Journal of Neurology 2003, 250(11):1335-1339.
146. Hulet S.W., Powers S., Connor J.R. Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains. Journal of Neurological Sciences 1999, 165(1):48-55.
147. Hung Y.H., Bush A.I., Cherny R.A. Copper in the brain and Alzheimer's disease. Journal of Biological Inorganic Chemistry 2010, 15(1):61-76.
148. Hwang Y.M., Stathopulos P.B., Dimmick K., Yang H., Badiei H.R., Tong M.S., et al. Nonamyloid aggregates arising from mature copper/zinc superoxide dismutases resemble those observed in amyotrophic lateral sclerosis. Journal of Biological Chemistry 2010, 285(53):41701-41711.
149. Ince P.G., Highley J.R., Kirby J., Wharton S.B., Takahashi H., Strong M.J., et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: An emerging molecular pathway and the significance of glial pathology. Acta Neuropathologica 2011, 122(6):657-671.
150. James S.A., Volitakis I., Adlard P.A., Duce J.A., Masters C.L., Cherny R.A., et al. Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. Free Radical Biology & Medicine 2012, 52(2):298-302.
151. Jellinger K.A. The role of iron in neurodegeneration: Prospects for pharmacotherapy of Parkinson's disease. Drugs & Aging 1999, 14(2):115-140.
152. Jellinger K.A. Apoptosis vs. nonapoptotic mechanisms in neurodegeneration. Neuroinflammation. Mechanisms and management 2003, 29-88. Humana Press, Totowa, NJ. P.L. Wood (Ed.).
153. Jellinger K.A. Infantile neuroaxonal dystrophy (Seitelberger disease). Developmental neuropathology 2004, 337-343. ISN Neuropath Press, Basel. J.A. Golden, B.N. Harding (Eds.).
154. Jellinger K.A. Basic mechanisms of neurodegeneration: A critical update. Journal of Cellular and Molecular Medicine 2010, 14(3):457-487.
155. Jellinger K.A. Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts. Movement Disorders 2012, 27(1):8-30.
156. Jellinger K.A. Challenges in the neuropathological diagnosis of dementias. International Journal of Neuropathology 2013, 1:8-52.
157. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D., et al. Iron-melanin complex in substantia nigra of parkinsonian brains: An x-ray microanalysis. Journal of Neurochemistry 1992, 59(3):1168-1171.
158. Jeyaraju D.V., Cisbani G., Pellegrini L. Calcium regulation of mitochondria motility and morphology. Biochimica et Biophysica Acta 2009, 1787(11):1363-1373.
159. Jiang D., Li X., Williams R., Patel S., Men L., Wang Y., et al. Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: Binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. Biochemistry 2009, 48(33):7939-7947.
160. Johnson C.J., Gilbert P.U., Abrecht M., Baldwin K.L., Russell R.E., Pedersen J.A., et al. Low copper and high manganese levels in prion protein plaques. Viruses 2013, 5(2):654-662.
161. Jomova K., Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology 2011, 283(2-3):65-87.
162. Jomova K., Vondrakova D., Lawson M., Valko M. Metals, oxidative stress and neurodegenerative disorders. Molecular and Cellular Biochemistry 2010, 345(1-2):91-104.
163. Karbowski M., Neutzner A. Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathologica 2012, 123(2):157-171.
164. Kawahara M. Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. Journal of Alzheimer's Disease 2005, 8(2):171-182. discussion 209-115.
165. Kawahara M., Kato-Negishi M. Link between aluminum and the pathogenesis of Alzheimer's disease: The integration of the aluminum and amyloid cascade hypotheses. International Journal of Alzheimer's Disease 2011, 2011:276393.
166. Ke Y., Qian Z.M. Brain iron metabolism: Neurobiology and neurochemistry. Progress in Neurobiology 2007, 83(3):149-173.
167. Kell D.B. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Archives of Toxicology 2010, 84(11):825-889.
168. Keogh M.J., Jonas P., Coulthard A., Chinnery P.F., Burn J. Neuroferritinopathy: A new inborn error of iron metabolism. Neurogenetics 2012, 13(1):93-96.
169. Khalid M., Aoun R.A., Mathews T.A. Altered striatal dopamine release following a sub-acute exposure to manganese. Journal of Neuroscience Methods 2011, 202(2):182-191.
170. Khalil M., Langkammer C., Ropele S., Petrovic K., Wallner-Blazek M., Loitfelder M., et al. Determinants of brain iron in multiple sclerosis: A quantitative 3T MRI study. Neurology 2011, 77(18):1691-1697.
171. Kienzl E., Jellinger K., Stachelberger H., Linert W. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?. Life Sciences 1999, 65(18-19):1973-1976.
172. Koeppen A.H., Kuntzsch E.C., Bjork S.T., Ramirez R., Mazurkiewicz J.E., Feustel P.J. Friedreich ataxia: metal dysmetabolism in dorsal root ganglia. Acta Neuropathologica Communications 2013, 1:26. 10.1186/2051-5960-1181-1126.
173. Kovacs G.G., Botond G., Budka H. Protein coding of neurodegenerative dementias: The neuropathological basis of biomarker diagnostics. Acta Neuropathologica 2010, 119(4):389-408.
174. Kozlowski H., Janicka-Klos A., Brasun J., Gaggelli E., Valensin D., Valensin G. Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation). Coordination Chemistry Reviews 2009, 253:2665-2685.
175. Kruer M.C., Hiken M., Gregory A., Malandrini A., Clark D., Hogarth P., et al. Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 2011, 134(Pt 4):947-958.
176. Kumar V., Bal A., Gill K.D. Aluminium-induced oxidative DNA damage recognition and cell-cycle disruption in different regions of rat brain. Toxicology 2009, 264(3):137-144.
177. Kurisaki H., Yomono H., Murayama S., Hebisawa A. Multiple system atrophy with a-/hypo-ceruloplasminemia: Distribution of iron in brains of 2 autopsy cases. Rinshō Shinkeigaku 2002, 42(4):293-298.
178. Langkammer C., Krebs N., Goessler W., Scheurer E., Ebner F., Yen K., et al. Quantitative MR imaging of brain iron: A postmortem validation study. Radiology 2010, 257(2):455-462.
179. Lassmann H., Bruck W., Lucchinetti C.F. The immunopathology of multiple sclerosis: An overview. Brain Pathology 2007, 17(2):210-218.
180. Lassmann H., van Horssen J., Mahad D. Progressive multiple sclerosis: Pathology and pathogenesis. Nature Reviews. Neurology 2012, 8(11):647-656.
181. Lee J.Y., Cho E., Seo J.W., Hwang J.J., Koh J.Y. Alteration of the cerebral zinc pool in a mouse model of Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2012, 71(3):211-222.
182. Lehn A., Boyle R., Brown H., Airey C., Mellick G. Neuroferritinopathy. Parkinsonism & Related Disorders 2012, 18(8):909-915.
183. Leskovjan A.C., Kretlow A., Lanzirotti A., Barrea R., Vogt S., Miller L.M. Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease. NeuroImage 2011, 55(1):32-38.
184. Levine S.M., Bilgen M., Lynch S.G. Iron accumulation in multiple sclerosis: An early pathogenic event. Expert Review of Neurotherapeutics 2013, 13(3):247-250.
185. LeVine S.M., Chakrabarty A. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Annals of the New York Academy of Sciences 2004, 1012:252-266.
186. Li X., Jankovic J., Le W. Iron chelation and neuroprotection in neurodegenerative diseases. Journal of Neural Transmission 2011, 118(3):473-477.
187. Li A., Paudel R., Johnson R., Courtney R., Lees A.J., Holton J.L., et al. Pantothenate kinase-associated neurodegeneration is not a synucleinopathy. Neuropathology and Applied Neurobiology 2012, 39:121-131.
188. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795.
189. Linder M.C. The relationship of copper to DNA damage and damage prevention in humans. Mutation Research 2012, 733(1-2):83-91.
190. Linert W., Herlinger E., Jameson R.F., Kienzl E., Jellinger K., Youdim M.B. Dopamine, 6-hydroxydopamine, iron, and dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochimica et Biophysica Acta 1996, 1316(3):160-168.
191. Liu Y., Connor J.R. Iron and ER stress in neurodegenerative disease. Biometals 2012, 25(4):837-845.
192. Liu X., Sullivan K.A., Madl J.E., Legare M., Tjalkens R.B. Manganese-induced neurotoxicity: The role of astroglial-derived nitric oxide in striatal interneuron degeneration. Toxicological Sciences 2006, 91(2):521-531.
193. Liu G., Zhang C., Yin J., Li X., Cheng F., Li Y., et al. α-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neuroscience Letters 2009, 454(3):187-192.
194. Loeb V., Yakunin E., Saada A., Sharon R. The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. The Journal of Biological Chemistry 2010, 285(10):7334-7343.
195. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Progress in Neurobiology 2009, 89(3):277-287.
196. Lopes K.O., Sparks D.L., Streit W.J. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia 2008, 56(10):1048-1060.
197. Lothian A., Hare D.J., Grimm R., Ryan T.M., Masters C.L., Roberts B.R. Metalloproteomics: principles, challenges and applications to neurodegeneration. Frontiers in Aging Neuroscience 2013, 5:35.
198. Lovell M.A., Markesbery W.R. Amyloid beta peptide, 4-hydroxynonenal and apoptosis. Current Alzheimer Research 2006, 3(4):359-364.
199. Luk K.C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J.Q., et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338(6109):949-953.
200. Lumsden A.L., Henshall T.L., Dayan S., Lardelli M.T., Richards R.I. Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Human Molecular Genetics 2007, 16(16):1905-1920.
201. Lutsenko S., Bhattacharjee A., Hubbard A.L. Copper handling machinery of the brain. Metallomics 2010, 2(9):596-608.
202. Lv Z., Jiang H., Xu H., Song N., Xie J. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. Journal of Neural Transmission 2011, 118(3):361-369.
203. Lyubartseva G., Lovell M.A. A potential role for zinc alterations in the pathogenesis of Alzheimer's disease. Biofactors 2012, 38(2):98-106.
204. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Annals of Neurology 1994, 36(6):876-881.
205. Manso Y., Adlard P.A., Carrasco J., Vasak M., Hidalgo J. Metallothionein and brain inflammation. Journal of Biological Inorganic Chemistry 2011, 16(7):1103-1113.
206. Martin W.R., Wieler M., Gee M. Midbrain iron content in early Parkinson disease: A potential biomarker of disease status. Neurology 2008, 70(16 Pt 2):1411-1417.
207. Massaad C.A., Klann E. Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxidants & Redox Signaling 2011, 14(10):2013-2054.
208. Mastroberardino P.G., Hoffman E.K., Horowitz M.P., Betarbet R., Taylor G., Cheng D., et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiology of Disease 2009, 34(3):417-431.
209. McNaught K.S., Belizaire R., Isacson O., Jenner P., Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Experimental Neurology 2003, 179(1):38-46.
210. Mehta V., Pei W., Yang G., Li S., Swamy E., Boster A., et al. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One 2013, 8(3):e57573.
211. Meloni G., Vasak M. Redox activity of alpha-synuclein-Cu is silenced by Zn(7)-metallothionein-3. Free Radical Biology & Medicine 2011, 50(11):1471-1479.
212. Milatovic D., Zaja-Milatovic S., Gupta R.C., Yu Y., Aschner M. Oxidative damage and neurodegeneration in manganese-induced neurotoxicity. Toxicology and Applied Pharmacology 2009, 240(2):219-225.
213. Miller Y., Ma B., Nussinov R. Zinc ions promote Alzheimer Abeta aggregation via population shift of polymorphic states. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(21):9490-9495.
214. Mills E., Dong X.P., Wang F., Xu H. Mechanisms of brain iron transport: Insight into neurodegeneration and CNS disorders. Future Medicinal Chemistry 2010, 2(1):51-64.
215. Miu A.C., Benga O. Aluminum and Alzheimer's disease: A new look. Journal of Alzheimer's Disease 2006, 10(2-3):179-201.
216. Miyajima H., Adachi J., Tatsuno Y., Takahashi Y., Fujimoto M., Kaneko E., et al. Increased very long-chain fatty acids in erythrocyte membranes of patients with aceruloplasminemia. Neurology 1998, 50(1):130-136.
217. Mizoroki T., Meshitsuka S., Maeda S., Murayama M., Sahara N., Takashima A. Aluminum induces tau aggregation in vitro but not in vivo. Journal of Alzheimer's Disease 2007, 11(4):419-427.
218. Mocchegiani E., Bertoni-Freddari C., Marcellini F., Malavolta M. Brain, aging and neurodegeneration: Role of zinc ion availability. Progress in Neurobiology 2005, 75(6):367-390.
219. Molina-Holgado F., Hider R.C., Gaeta A., Williams R., Francis P. Metals ions and neurodegeneration. Biometals 2007, 20(3-4):639-654.
220. Montine K.S., Quinn J.F., Zhang J., Fessel J.P., Roberts L.J., Morrow J.D., et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chemistry and Physics of Lipids 2004, 128(1-2):117-124.
221. Morris D.R., Levenson C.W. Ion channels and zinc: Mechanisms of neurotoxicity and neurodegeneration. Journal of Toxicology 2012, 2012:785647.
222. Mot A.I., Wedd A.G., Sinclair L., Brown D.R., Collins S.J., Brazier M.W. Metal attenuating therapies in neurodegenerative disease. Expert Review of Neurotherapeutics 2011, 11(12):1717-1745.
223. Mounsey R.B., Teismann P. Chelators in the treatment of iron accumulation in Parkinson's disease. International Journal of Cell Biology 2012, 2012:983245.
224. Muhoberac B.B., Vidal R. Abnormal iron homeostasis and neurodegeneration. Frontiers in Aging Neuroscience 2013, 5:32.
225. Munch G., Luth H.J., Wong A., Arendt T., Hirsch E., Ravid R., et al. Crosslinking of alpha-synuclein by advanced glycation endproducts-An early pathophysiological step in Lewy body formation?. Journal of Chemical Neuroanatomy 2000, 20(3-4):253-257.
226. Nakahara J., Maeda M., Aiso S., Suzuki N. Current concepts in multiple sclerosis: Autoimmunity versus oligodendrogliopathy. Clinical Reviews in Allergy & Immunology 2012, 42(1):26-34.
227. Nubling G., Bader B., Levin J., Hildebrandt J., Kretzschmar H., Giese A. Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with alpha-synuclein at the single molecule level. Molecular Neurodegeneration 2012, 7:35.
228. Nunez M.T., Urrutia P., Mena N., Aguirre P., Tapia V., Salazar J. Iron toxicity in neurodegeneration. Biometals 2012, 25(4):761-776.
229. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007, 68(21):1820-1825.
230. Oettinghaus B., Licci M., Scorrano L., Frank S. Less than perfect divorces: Dysregulated mitochondrial fission and neurodegeneration. Acta Neuropathologica 2012, 123(2):189-203.
231. Olanow C.W. Manganese-induced parkinsonism and Parkinson's disease. Annals of the New York Academy of Sciences 2004, 1012:209-223.
232. Olivares D., Huang X., Branden L., Greig N.H., Rogers J.T. Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element. International Journal of Molecular Sciences 2009, 10(3):1226-1260.
233. Orr A.L., Li S., Wang C.E., Li H., Wang J., Rong J., et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. The Journal of Neuroscience 2008, 28(11):2783-2792.
234. Ortega R., Cloetens P., Deves G., Carmona A., Bohic S. Iron storage within dopamine neurovesicles revealed by chemical nano-imaging. PLoS One 2007, 2(9):e925.
235. Oteiza P.I., Mackenzie G.G., Verstraeten S.V. Metals in neurodegeneration: Involvement of oxidants and oxidant-sensitive transcription factors. Molecular Aspects of Medicine 2004, 25(1-2):103-115.
236. Palmieri B., Sblendorio V. Oxidative stress tests: Overview on reliability and use. Part I. European Review for Medical and Pharmacological Sciences 2007, 11(5):309-342.
237. Pamphlett R., Kum Jew S. Uptake of inorganic mercury by human locus ceruleus and corticomotor neurons: implications for amyotrophic lateral sclerosis. Acta Neuropathologica Communications 2013, 1:13. 10.1186/2051-5960-1181-1113.
238. Parihar M.S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cellular and Molecular Life Sciences 2008, 65(7-8):1272-1284.
239. Pandolfo M., Pastore A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. Journal of Neurology 2009, 256(Suppl 1):9-17.
240. Parker S.J., Koistinaho J., White A.R., Kanninen K.M. Biometals in rare neurodegenerative disorders of childhood. Frontiers in Aging Neuroscience 2013, 5:14. 10.3389/fnagi.2013.00014.
241. Pastore A. Mechanisms and metal involvement in neurodegenerative diseases. Mechanisms and metal involvement in neurodegenerative diseases 2013, 98-117. The Royal Society of Chemistry, London, UK. R. Ward, R. Crichton, D. Dexter (Eds.).
242. Peneder T.M., Scholze P., Berger M.L., Reither H., Heinze G., Bertl J., et al. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice. Neuroscience 2011, 180:280-292.
243. Percy M.E., Kruck T.P., Pogue A.I., Lukiw W.J. Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease. Journal of Inorganic Biochemistry 2011, 105(11):1505-1512.
244. Perl D.P., Moalem S. Aluminum and Alzheimer's disease, a personal perspective after 25 years. Journal of Alzheimer's Disease 2006, 9(3 Suppl):291-300.
245. Pivovarova N.B., Andrews S.B. Calcium-dependent mitochondrial function and dysfunction in neurons. The FEBS Journal 2010, 277(18):3622-3636.
246. Post J.I., Eibl J.K., Ross G.M. Zinc induces motor neuron death via a selective inhibition of brain-derived neurotrophic factor activity. Amyotrophic Lateral Sclerosis 2008, 9(3):149-155.
247. Prabhakaran K., Chapman G.D., Gunasekar P.G. alpha-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-kappaB-mediated pathway. Toxicology Mechanisms and Methods 2011, 21(6):435-443.
248. Prabhakaran K., Ghosh D., Chapman G.D., Gunasekar P.G. Molecular mechanism of manganese exposure-induced dopaminergic toxicity. Brain Research Bulletin 2008, 76(4):361-367.
249. Przedborski S. Inflammation and Parkinson's disease pathogenesis. Movement Disorders 2010, 25(Suppl 1):S55-S57.
250. Ramalingam M., Kim S.J. Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases. Journal of Neural Transmission 2012, 119(8):891-910.
251. Reusche E., Koch V., Lindner B., Harrison A.P., Friedrich H.J. Alzheimer morphology is not increased in dialysis-associated encephalopathy and long-term hemodialysis. Acta Neuropathologica 2001, 101(3):211-216.
252. Reynolds R., Crichton R. Multiple sclerosis. Mechanisms and metal involvement in neurodegenerative diseases 2013, 163-185. The Royal Society of Chemistry, London, UK. R. Ward, R. Crichton, D. Dexter (Eds.).
253. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. Journal of Neurochemistry 1989, 52(2):515-520.
254. Rivera-Mancia S., Perez-Neri I., Rios C., Tristan-Lopez L., Rivera-Espinosa L., Montes S. The transition metals copper and iron in neurodegenerative diseases. Chemico-Biological Interactions 2010, 186(2):184-199.
255. Roberts B.R., Tainer J.A., Getzoff E.D., Malencik D.A., Anderson S.R., Bomben V.C., et al. Structural characterization of zinc-deficient human superoxide dismutase and implications for ALS. Journal of Molecular Biology 2007, 373(4):877-890.
256. Rodella L.F., Ricci F., Borsani E., Stacchiotti A., Foglio E., Favero G., et al. Aluminium exposure induces Alzheimer's disease-like histopathological alterations in mouse brain. Histology and Histopathology 2008, 23(4):433-439.
257. Roos P.M., Vesterberg O., Nordberg M. Metals in motor neuron diseases. Experimental Biology and Medicine (Maywood, N.J.) 2006, 231(9):1481-1487.
258. Ropele S., de Graaf W., Khalil M., Wattjes M.P., Langkammer C., Rocca M.A., et al. MRI assessment of iron deposition in multiple sclerosis. Journal of Magnetic Resonance Imaging 2011, 34(1):13-21.
259. Rosas H.D., Chen Y.I., Doros G., Salat D.H., Chen N.K., Kwong K.K., et al. Alterations in brain transition metals in Huntington disease: An evolving and intricate story. Archives of Neurology 2012, 69(7):887-893.
260. Roth J.A. Are there common biochemical and molecular mechanisms controlling manganism and parkisonism. Neuromolecular Medicine 2009, 11(4):281-296.
261. Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Annals of Neurology 2009, 65(Suppl 1):S3-S9.
262. Rouault T.A. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nature Reviews. Neuroscience 2013, 14(8):551-564.
263. Rowinska-Zyrek M., Valensin D., Luczkowski M., Kozlowski H. Mechanisms and metal involvement in neurodegenerative diseases. Mechanisms and metal involvement in neurodegenerative diseases 2013, 118-162. The Royal Society of Chemistry, London, UK. R. Ward, R. Crichton, D. Dexter (Eds.).
264. Ruiperez V., Darios F., Davletov B. Alpha-synuclein, lipids and Parkinson's disease. Progress in Lipid Research 2010, 49(4):420-428.
265. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(47):18578-18583.
266. Salvador G.A. Iron in neuronal function and dysfunction. Biofactors 2010, 36(2):103-110.
267. SanMartin C.D., Paula-Lima A.C., Hidalgo C., Nunez M.T. Sub-lethal levels of amyloid beta-peptide oligomers decrease non-transferrin-bound iron uptake and do not potentiate iron toxicity in primary hippocampal neurons. Biometals 2012, 25(4):805-813.
268. Santner A., Uversky V.N. Metalloproteomics and metal toxicology of alpha-synuclein. Metallomics 2010, 2(6):378-392.
269. Santos R., Lefevre S., Sliwa D., Seguin A., Camadro J.M., Lesuisse E. Friedreich ataxia: Molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxidants & Redox Signaling 2010, 13(5):651-690.
270. Savelieff M.G., Lee S., Liu Y., Lim M.H. Untangling amyloid-beta, tau, and metals in Alzheimer's disease. ACS Chemical Biology 2013, 8(5):856-865.
271. Savory J., Herman M.M., Ghribi O. Mechanisms of aluminum-induced neurodegeneration in animals: Implications for Alzheimer's disease. Journal of Alzheimer's Disease 2006, 10(2-3):135-144.
272. Schipper H.M. Neurodegeneration with brain iron accumulation-Clinical syndromes and neuroimaging. Biochimica et Biophysica Acta 2012, 1822(3):350-360.
273. Schipper H.M., Song W., Zukor H., Hascalovici J.R., Zeligman D. Heme oxygenase-1 and neurodegeneration: Expanding frontiers of engagement. Journal of Neurochemistry 2009, 110(2):469-485.
274. Schneider S.A., Hardy J., Bhatia K.P. Syndromes of neurodegeneration with brain iron accumulation (NBIA): An update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Movement Disorders 2012, 27(1):42-53.
275. Schneider S.A., Zorzi G., Nardocci N. Pathophysiology and treatment of neurodegeneration with brain iron accumulation in the pediatric population. Current Treatment Options in Neurology 2013, 15(5):652-667.
276. Schon E.A., Przedborski S. Mitochondria: The next (neurode)generation. Neuron 2011, 70(6):1033-1053.
277. Schrag M., Mueller C., Oyoyo U., Smith M.A., Kirsch W.M. Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Progress in Neurobiology 2011, 94(3):296-306.
278. Seguin A., Sutak R., Bulteau A.L., Garcia-Serres R., Oddou J.L., Lefevre S., et al. Evidence that yeast frataxin is not an iron storage protein in vivo. Biochimica et Biophysica Acta 2010, 1802(6):531-538.
279. Shamoto-Nagai M., Maruyama W., Yi H., Akao Y., Tribl F., Gerlach M., et al. Neuromelanin induces oxidative stress in mitochondria through release of iron: Mechanism behind the inhibition of 26S proteasome. Journal of Neural Transmission 2006, 113(5):633-644.
280. Shavali S., Brown-Borg H.M., Ebadi M., Porter J. Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neuroscience Letters 2008, 439(2):125-128.
281. Shcherbatykh I., Carpenter D.O. The role of metals in the etiology of Alzheimer's disease. Journal of Alzheimer's Disease 2007, 11(2):191-205.
282. Sheline C.T., Zhu J., Zhang W., Shi C., Cai A.L. Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo. Neurodegenerative Diseases 2013, 11(1):49-58.
283. Shimanouchi T., Onishi R., Kitaura N., Umakoshi H., Kuboi R. Copper-mediated growth of amyloid beta fibrils in the presence of oxidized and negatively charged liposomes. Journal of Bioscience and Bioengineering 2011, 112(6):611-615.
284. Shin R.W. Interaction of aluminum with paired helical filament tau is involved in neurofibrillary pathology of Alzheimer's disease. Gerontology 1997, 43(Suppl 1):16-23.
285. Sian-Hulsmann J., Mandel S., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Journal of Neurochemistry 2011, 118(6):939-957.
286. Singh B.K., Kumar A., Ahmad I., Kumar V., Patel D.K., Jain S.K., et al. Oxidative stress in zinc-induced dopaminergic neurodegeneration: Implications of superoxide dismutase and heme oxygenase-1. Free Radical Research 2011, 45(10):1207-1222.
287. Singh N., Haldar S., Tripathi A.K., McElwee M., Horback K., Anbalagan C. Iron-mediated protein aggregation in prion disorders and Parkinson's disease. Antioxid Redox Signal 2013, in print.
288. Smith M.A., Casadesus G., Joseph J.A., Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radical Biology & Medicine 2002, 33(9):1194-1199.
289. Smith A.P., Lee N.M. Role of zinc in ALS. Amyotrophic Lateral Sclerosis 2007, 8(3):131-143.
290. Smith M.A., Zhu X., Tabaton M., Liu G., McKeel D.W., Cohen M.L., et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. Journal of Alzheimer's Disease 2010, 19(1):363-372.
291. Spadoni F., Stefani A., Morello M., Lavaroni F., Giacomini P., Sancesario G. Selective vulnerability of pallidal neurons in the early phases of manganese intoxication. Experimental Brain Research 2000, 135(4):544-551.
292. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388(6645):839-840.
293. Squitti R. Copper dysfunction in Alzheimer's disease: From meta-analysis of biochemical studies to new insight into genetics. Journal of Trace Elements in Medicine and Biology 2012, 26(2-3):93-96.
294. Squitti R. Metals in Alzheimer's disease: A systemic perspective. Frontiers in Bioscience 2012, 17:451-472.
295. Squitti R., Polimanti R. Copper phenotype in Alzheimer's disease: Dissecting the pathway. American Journal of Neurodegenerative Disease 2013, 2(2):46-56.
296. Stankiewicz J., Panter S.S., Neema M., Arora A., Batt C.E., Bakshi R. Iron in chronic brain disorders: Imaging and neurotherapeutic implications. Neurotherapeutics 2007, 4(3):371-386.
297. Sultana R., Butterfield D.A. Role of oxidative stress in the progression of Alzheimer's disease. Journal of Alzheimer's Disease 2010, 19(1):341-353.
298. Taba P. Metals and movement disorders. Current Opinion in Neurology 2013, 26(4):435-441.
299. Tabner B.J., El-Agnaf O.M., German M.J., Fullwood N.J., Allsop D. Protein aggregation, metals and oxidative stress in neurodegenerative diseases. Biochemical Society Transactions 2005, 33(Pt 5):1082-1086.
300. Takanashi M., Mochizuki H., Yokomizo K., Hattori N., Mori H., Yamamura Y., et al. Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP). Parkinsonism & Related Disorders 2001, 7(4):311-314.
301. Tamagno E., Guglielmotto M., Aragno M., Borghi R., Autelli R., Giliberto L., et al. Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. Journal of Neurochemistry 2008, 104(3):683-695.
302. Telpoukhovskaia M.A., Orvig C. Werner coordination chemistry and neurodegeneration. Chemical Society Reviews 2013, 42(4):1836-1846.
303. Thomas M., Jankovic J. Neurodegenerative disease and iron storage in the brain. Current Opinion in Neurology 2004, 17(4):437-442.
304. Thompson K.J., Shoham S., Connor J.R. Iron and neurodegenerative disorders. Brain Research Bulletin 2001, 55(2):155-164.
305. Tiffany-Castiglioni E., Hong S., Qian Y. Copper handling by astrocytes: Insights into neurodegenerative diseases. International Journal of Developmental Neuroscience 2011, 29(8):811-818.
306. Tougu V., Karafin A., Zovo K., Chung R.S., Howells C., West A.K., et al. Zn(II)- and Cu(II)-induced non-fibrillar aggregates of amyloid-beta (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators. Journal of Neurochemistry 2009, 110(6):1784-1795.
307. Trushina E., Dyer R.B., Badger J.D., Ure D., Eide L., Tran D.D., et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Molecular and Cellular Biology 2004, 24(18):8195-8209.
308. Uversky V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. Journal of Neurochemistry 2007, 103(1):17-37.
309. Valiente-Gabioud A.A., Torres-Monserrat V., Molina-Rubino L., Binolfi A., Griesinger C., Fernandez C.O. Structural basis behind the interaction of Zn(2)(+) with the protein alpha-synuclein and the Abeta peptide: A comparative analysis. Journal of Inorganic Biochemistry 2012, 117:334-341.
310. Valko M., Morris H., Cronin M.T. Metals, toxicity and oxidative stress. Current Medicinal Chemistry 2005, 12(10):1161-1208.
311. Verina T., Kiihl S.F., Schneider J.S., Guilarte T.R. Manganese exposure induces microglia activation and dystrophy in the substantia nigra of non-human primates. Neurotoxicology 2011, 32(2):215-226.
312. Vidal R., Delisle M.B., Rascol O., Ghetti B. Hereditary ferritinopathies. Neurodegeneration: The molecular pathology of dementia and movement disorders 2011, 461-466. Blackwell, Oxford. 2nd ed. D.W. Dickson, R.O. Weller (Eds.).
313. Vonk W.I., Klomp L.W. Role of transition metals in the pathogenesis of amyotrophic lateral sclerosis. Biochemical Society Transactions 2008, 36(Pt 6):1322-1328.
314. Wallis L.I., Paley M.N., Graham J.M., Grunewald R.A., Wignall E.L., Joy H.M., et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. Journal of Magnetic Resonance Imaging 2008, 28(5):1061-1067.
315. Walsh A.J., Lebel R.M., Eissa A., Blevins G., Catz I., Lu J.Q., et al. Multiple sclerosis: Validation of MR imaging for quantification and detection of iron. Radiology 2013, 267:531-542.
316. Walton J.R. Evidence for participation of aluminum in neurofibrillary tangle formation and growth in Alzheimer's disease. Journal of Alzheimer's Disease 2010, 22(1):65-72.
317. Walton J.R. Aluminum disruption of calcium homeostasis and signal transduction resembles change that occurs in aging and Alzheimer's disease. Journal of Alzheimer's Disease 2012, 29(2):255-273.
318. Walton J.R. Aluminum involvement in the progression of Alzheimer's disease. Journal of Alzheimer's Disease 2013, 35(1):7-43.
319. Walton J.R., Wang M.X. APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer's disease. Journal of Inorganic Biochemistry 2009, 103(11):1548-1554.
320. Wang C.Y., Wang T., Zheng W., Zhao B.L., Danscher G., Chen Y.H., et al. Zinc overload enhances APP cleavage and Abeta deposition in the Alzheimer mouse brain. PLoS One 2010, 5(12):e15349.
321. Mechanisms and metal involvement in neurodegenerative diseases 2013, The Royal Society of Chemistry, London, UK. R. Ward, R. Crichton, D. Dexter (Eds.).
322. Watt N.T., Taylor D.R., Kerrigan T.L., Griffiths H.H., Rushworth J.V., Whitehouse I.J., et al. Prion protein facilitates uptake of zinc into neuronal cells. Nature Communications 2012, 3:1134.
323. Wegrzynowicz M., Holt H.K., Friedman D.B., Bowman A.B. Changes in the striatal proteome of YAC128Q mice exhibit gene-environment interactions between mutant huntingtin and manganese. Journal of Proteome Research 2012, 11(2):1118-1132.
324. White A.R., Barnham K.J., Huang X., Voltakis I., Beyreuther K., Masters C.L., et al. Iron inhibits neurotoxicity induced by trace copper and biological reductants. Journal of Biological Inorganic Chemistry 2004, 9(3):269-280.
325. Williams R., Rohr A.M., Wang W.T., Choi I.Y., Lee P., Berman N.E., et al. Iron deposition is independent of cellular inflammation in a cerebral model of multiple sclerosis. BMC Neuroscience 2011, 12:59.
326. Wu Z., Du Y., Xue H., Wu Y., Zhou B. Aluminum induces neurodegeneration and its toxicity arises from increased iron accumulation and reactive oxygen species (ROS) production. Neurobiology of Aging 2012, 33(1):199.
327. Wypijewska A., Galazka-Friedman J., Bauminger E.R., Wszolek Z.K., Schweitzer K.J., Dickson D.W., et al. Iron and reactive oxygen species activity in parkinsonian substantia nigra. Parkinsonism & Related Disorders 2010, 16(5):329-333.
328. Yokel R.A. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. Journal of Alzheimer's Disease 2006, 10(2-3):223-253.
329. Youdim M.B. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotoxicity Research 2008, 14(1):45-56.
330. Yumoto S., Kakimi S., Ohsaki A., Ishikawa A. Demonstration of aluminum in amyloid fibers in the cores of senile plaques in the brains of patients with Alzheimer's disease. Journal of Inorganic Biochemistry 2009, 103(11):1579-1584.
331. Zatta P., Lucchini R., van Rensburg S.J., Taylor A. The role of metals in neurodegenerative processes: Aluminum, manganese, and zinc. Brain Research Bulletin 2003, 62(1):15-28.
332. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nature Reviews Neuroscience 2004, 5(11):863-873.
333. Zhang X., Haaf M., Todorich B., Grosstephan E., Schieremberg H., Surguladze N., et al. Cytokine toxicity to oligodendrocyte precursors is mediated by iron. Glia 2005, 52(3):199-208.
334. Zhang Q.L., Jia L., Jiao X., Guo W.L., Ji J.W., Yang H.L., et al. APP/PS1 transgenic mice treated with aluminum: An update of Alzheimer's disease model. International Journal of Immunopathology and Pharmacology 2012, 25(1):49-58.
335. Zheng W., Monnot A.D. Regulation of brain iron and copper homeostasis by brain barrier systems: Implication in neurodegenerative diseases. Pharmacology and Therapeutics 2012, 133(2):177-188.
336. Zhou Z.D., Lan Y.H., Tan E.K., Lim T.M. Iron species-mediated dopamine oxidation, proteasome inhibition, and dopaminergic cell demise: Implications for iron-related dopaminergic neuron degeneration. Free Radical Biology & Medicine 2010, 49(12):1856-1871.
337. Zhu X., Raina A.K., Lee H.G., Casadesus G., Smith M.A., Perry G. Oxidative stress signalling in Alzheimer's disease. Brain Research 2004, 1000(1-2):32-39.
338. Zivadinov R., Weinstock-Guttman B., Pirko I. Iron deposition and inflammation in multiple sclerosis. Which one comes first?. BMC Neuroscience 2011, 12:60.
339. Zucca F.A., Bellei C., Giannelli S., Terreni M.R., Gallorini M., Rizzio E., et al. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: Consequences for neuronal vulnerability. Journal of Neural Transmission 2006, 113(6):757-767.
340. Zucconi G.G., Cipriani S., Scattoni R., Balgkouranidou I., Hawkins D.P., Ragnarsdottir K.V. Copper deficiency elicits glial and neuronal response typical of neurodegenerative disorders. Neuropathology and Applied Neurobiology 2007, 33(2):212-225.